The correlation between zinc and insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer

Daragó, Adam; Sapota, Andrzej; Matych, Józef; Nasiadek, Marzenna; Skrzypińska-Gawrysiak, Małgorzata; Kilanowicz, Anna

doi:10.1515/cclm.2011.651

Cited by 18 publications

(25 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant decrease was observed (effect size = −1.36; 95% CI, −1.97 to −0.75) using random effects model-meta-analysis of 7 studies [79]–[85] (2985 cases, 3539 controls, Fig. 4).…”

Section: Resultsmentioning

confidence: 97%

Serum and Tissue Zinc in Epithelial Malignancies: A Meta-Analysis

et al. 2014

View full text Add to dashboard Cite

Background and ObjectivesCurrent studies give us inconsistent results regarding the association of neoplasms and zinc(II) serum and tissues concentrations. The results of to-date studies using meta-analysis are summarized in this paper.MethodsWeb of Science (Science citation index expanded), PubMed (Medline), Embase and CENTRAL were searched. Articles were reviewed by two evaluators; quality was assessed by Newcastle-Ottawa scale; meta-analysis was performed including meta-regression and publication bias analysis.ResultsAnalysis was performed on 114 case control, cohort and cross-sectional studies of 22737 participants. Decreased serum zinc level was found in patients with lung (effect size = −1.04), head and neck (effect size = −1.43), breast (effect size = −0.93), liver (effect size = −2.29), stomach (effect size = −1.59), and prostate (effect size = −1.36) cancers; elevation was not proven in any tumor. More specific zinc patterns are evident at tissue level, showing increase in breast cancer tissue (effect size = 1.80) and decrease in prostatic (effect size = −3.90), liver (effect size = −8.26), lung (effect size = −3.12), and thyroid cancer (effect size = −2.84). The rest of the included tumors brought ambiguous results, both in serum and tissue zinc levels across the studies. The association between zinc level and stage or grade of tumor has not been revealed by meta-regression.ConclusionThis study provides evidence on cancer-specific tissue zinc level alteration. Although serum zinc decrease was associated with most tumors mentioned herein, further – prospective - studies are needed.

show abstract

Section: Resultsmentioning

confidence: 97%

Serum and Tissue Zinc in Epithelial Malignancies: A Meta-Analysis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…However, another recent clinical study has indicated that IGF1 is positively associated and IGFBP3 is inversely associated with allcause mortality in men with advanced prostate cancer (Rowlands et al 2012), indicating that levels of IGF1 and IGFBP3 may have potential as prognostic markers in predicting risk of death in men with advanced prostate cancer. A comparable study has revealed a correlation between zinc, IGF1, and IGFBP3 concentrations, and prostate-specific antigen in prostate cancer, and findings have indicated that zinc, IGF1, and IGFBP3 can be useful in early diagnosis of prostate cancer (Darago et al 2011). In addition, other investigators reported that IGFBP3 gene polymorphism would be associated with the susceptibility to develop prostate cancer (Safarinejad et al 2011a).…”

Section: Ilp Molecules and Cancer Riskmentioning

confidence: 92%

Insulin resistance and cancer: the role of insulin and IGFs

Djiogue¹,

Kamdje²,

Vecchio³

et al. 2012

Endocrine-Related Cancer

229

188

View full text Add to dashboard Cite

Insulin, IGF1, and IGF2 are the most studied insulin-like peptides (ILPs). These are evolutionary conserved factors well known as key regulators of energy metabolism and growth, with crucial roles in insulin resistance-related metabolic disorders such as obesity, diseases like type 2 diabetes mellitus, as well as associated immune deregulations. A growing body of evidence suggests that insulin and IGF1 receptors mediate their effects on regulating cell proliferation, differentiation, apoptosis, glucose transport, and energy metabolism by signaling downstream through insulin receptor substrate molecules and thus play a pivotal role in cell fate determination. Despite the emerging evidence from epidemiological studies on the possible relationship between insulin resistance and cancer, our understanding on the cellular and molecular mechanisms that might account for this relationship remains incompletely understood. The involvement of IGFs in carcinogenesis is attributed to their role in linking high energy intake, increased cell proliferation, and suppression of apoptosis to cancer risks, which has been proposed as the key mechanism bridging insulin resistance and cancer. The present review summarizes and discusses evidence highlighting recent advances in our understanding on the role of ILPs as the link between insulin resistance and cancer and between immune deregulation and cancer in obesity, as well as those areas where there remains a paucity of data. It is anticipated that issues discussed in this paper will also recover new therapeutic targets that can assist in diagnostic screening and novel approaches to controlling tumor development.

show abstract

“…IGF2 does not act in isolation during carcinogenesis but is modulated positively and negatively by other components of the system, which may themselves have prognostic value. For example, over-expression of IGF1R is associated with more aggressive tumours (Hakam et al 1999) and IGFBP3 may have a role both in early diagnosis (Darago et al 2011) and prediction of death (Rowlands et al 2012) in prostate cancer and in prediction of risk of colorectal cancer (Wu et al 2011). In view of this, a more accurate assessment of an individual's cancer risk or prognosis may be to combine a panel of measurements as an index.…”

Section: Potential Utilitymentioning

confidence: 99%

IGF2 and cancer

Livingstone¹

2013

Endocrine-Related Cancer

254

227

View full text Add to dashboard Cite

Insulin-like growth factor 2 (IGF2) is a 7.5 kDa mitogenic peptide hormone expressed by liver and many other tissues. It is three times more abundant in serum than IGF1, but our understanding of its physiological and pathological roles has lagged behind that of IGF1. Expression of the IGF2 gene is strictly regulated. Over-expression occurs in many cancers and is associated with a poor prognosis. Elevated serum IGF2 is also associated with increased risk of developing various cancers including colorectal, breast, prostate and lung. There is established clinical utility for IGF2 measurement in the diagnosis of non-islet cell tumour hypoglycaemia, a condition characterised by a molar IGF2:IGF1 ratio O10. Recent advances in understanding of the pathophysiology of IGF2 in cancer have suggested much novel clinical utility for its measurement. Measurement of IGF2 in blood and genetic and epigenetic tests of the IGF2 gene may help assess cancer risk and prognosis. Further studies will determine whether these tests enter clinical practice. New therapeutic approaches are being developed to target IGF2 action. This review provides a clinical perspective on IGF2 and an update on recent research findings.

show abstract

The correlation between zinc and insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer

Cited by 18 publications

References 33 publications

Serum and Tissue Zinc in Epithelial Malignancies: A Meta-Analysis

Serum and Tissue Zinc in Epithelial Malignancies: A Meta-Analysis

Insulin resistance and cancer: the role of insulin and IGFs

IGF2 and cancer

Contact Info

Product

Resources

About